Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline
MarketBeat·September 22, 2026
Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics man...
This article was sourced from MarketBeat. Read the full article at the original publisher.
Read full article at MarketBeat →